The Anthracycline-Induced Cardiomyopathy in Patient with Breast Cancer (The Description of the Case and Review of the Literature)
K.A. Tregubov, I.I. Reznik, P.A. Klimov
pp. 30-35
Ural State Medical University, Yekaterinburg, Russian Federation;
FKUZ «5 Military Clinical Hospital of the MIA of Russia», Yekaterinburg, Russian Federation
DOI: 10.22138/2500-0918-2016-14-2-30-35
Abstract. The article provides the analysis of clinical cases of examination and treatment of the patient with a relatively rare disease in the clinic of internal diseases — anthracycline-induced cardiomyopathy. Also consider some questions about the prevalence, pathogenesis, clinical presentation, diagnostic capabilities, treatment and prevention of anthracycline-induced cardiomyopathy.
Keywords: anthracycline cardiotoxicity, cardiomyopathy, heart failure
REFERENCES
1. Curigliano G1, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.
2. Von Hoff DD, Layard MW, Bas5a P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7.
3. Vergely C, Delemasure S, Cottin Y, Rochette L. Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab 2007; 35: 1–7.
4. Singal PK, Iliscovic N, Timao U et al. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11 (12): 931–6.
5. Doroshow JH. Doxorubicin-induced cardiototoxicity. N Engl J Med 1991; 324: 843–45.
6. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure J Physiol 2003; 555 (1): 1–13.
7. Bovelli D, Plataniotis G, Roila F et al. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl. 5): 423–428.
8. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109 (22): 2749–54.
9. Sawaya H, Sebag IA, Plana JC et al. Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients treated with Anthracyclines, Taxanes and Trastuzumab Circ Cardiovasc Imaging 2012; 5 (5): 596–603.
10. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 1: 710–7.
11. Tallaj JA, Franco V, Rayburn BK et al. Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. J Heart Lung Transplant 2005; 24: 2196–201.
12. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy. J Am Coll Cardiol 2010; 55 (3): 213–20.
13. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48 (11): 2258–62.
14. Cardinale D, Colombo A, Sandri MT. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114 (23):2474–81.
15. Georgakopoulos P, Roussou P, Matsakas E. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallelgroup, randomized, controlled study with 36-month follow-up. Am J Hematol 2010; 85 (11).
16. Tallarico D, Rizzo V, Di Mario V. Miocardial cytoprotection by trimetazidine against anthracycline-induced Cardiotoxicity in anticancer chemotherapy. Angiology 2003; Mar-Apr; 54 (2): 219-27.
17. Vatutin N.T., Kalinkina N.V., Rigok V.V., Stolica О.I. Effect of trimetazidine on heart rate variability and left ventricular diastolic dysfunction in patients receiving anthracycline antibiotics. Bulletin of Kharkiv National University named after VN Karazin. 658/2005; pp 46-51.
18. Acar Z, Kale A, Turgut M, Demircan S, Durna K. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2011; Aug 23; 58(9): 988-9.
19. Reznikova E.А., Kosenok V.К., Nechaeva G. I., Merculov V.N., Reznicov А.S. Effect of the drug on reamberin cardiotoxicity of anthracyclines in the treatment of locally advanced breast cancer. Bulletin of St. Petersburg State Medical Academy named after II Mechnikov. 2004. No. 4. pp. 123–126.
20. Cardiology. National leadership. Delenkov U.N. et al. Edited by Belencov U.N., Organov R.G. – М.:GEOTAR – Media, 2008. pp. 887–900.
21. Mareev V.U., Ageev F.Т., Arutunov G.P., Koroteev А.V., Маreev U.V., Оvchinnicov А.G. National guidelines PRAs, the RKO and RNMOT for the diagnosis and treatment of chronic heart failure (fourth revision), 2013.
22. Willenheimer R., van Veldhuisen D.J., Silke B., et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-2435.
23. Vasyuk Y.А, Scolnic E.L., et al. Anthracycline cardiotoxicity: prospects for the use of ivabradine. Kardiosomatika. 2012. No. 3. Pp. 65–69.
Authors:
Tregubov Konstantin A.
FKUZ «5 Military Clinical Hospital of the MIA of Russia».
Head of the cardiology department.
Russian Federation, 620036, Yekaterinburg, 10 Soboleva str.
katregubov@mail.ru
Reznik Inna I.
Ural State Medical University Ministry
Doctor of Medical Sciences, Professor of the Department of therapy faculty training and professional retraining.
Russian Federation, 620219, Yekaterinburg, 3 Repina St.
inna-reznik2008@yandex.ru
Klimov Pavel A.
FKUZ «5 Military Clinical Hospital of the MIA of Russia».
Head of Cabinet of extracorporeal methods of detoxification.
Russian Federation, 620036, Yekaterinburg, 10 Soboleva St.
Received – 01.04.2016
For citation:
Tregubov K.A., Reznik I.I., Klimov P.A. The Anthracycline-induced Cardiomyopathy in Patient with Breast Cancer (The description of the case and review of the literature). [Antratsiklin-indutsirovannaya kardiomiopatiya u patsientki s rakom molochnoi zhelezy (opisanie sluchaya I obzor literatury)] Vestnik uralskoi meditsinskoi akademicheskoi nauki – Vestn. Ural. Med. Akad. Nauki. 2016, no. 2, pp. 30-35. DOI: 10.22138/2500-0918-2016-14-2-30-35 [In Russ.]